Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.
about
Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile.Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myelomaInternal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.Survival and proliferation factors of normal and malignant plasma cells.Thalidomide for the treatment of multiple myeloma.PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor.Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome.Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma.An Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma.Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.
P2860
Q33379155-3531DF22-D287-4A59-9E18-0B01510C3874Q33787031-69DF7C33-1429-49FD-AE43-FCA64C506065Q33880085-E55EF8B9-02FC-44C7-B05F-DBACE1E865E1Q35211028-2A435E90-F8D4-4216-AAD9-1250848968AEQ35870500-600E2A76-06C2-4AA7-8C64-5DB2907C985CQ36126937-BD3E2839-856F-43E7-89D9-94B5EA7595B6Q36907272-C18C1823-20AA-4503-A191-FE6A51448B01Q38868904-75F00002-1227-43A4-86EB-3168FE7DC2A8Q44163682-4DF3CEF2-B1CC-442D-BD81-F44B747AF82CQ44846244-DB98B5DE-5813-4256-8DD0-3FBE6C8744C2Q49901829-F8F09587-EBBC-460C-B129-199C5D428DFAQ50228598-C46BB893-A0AF-4076-A9ED-F3999642A536Q52718642-38638E7B-A49C-46A8-BC98-3F3D0E6ADCA8
P2860
Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Elevated level of plasma basic ...... th increased disease activity.
@en
type
label
Elevated level of plasma basic ...... th increased disease activity.
@en
prefLabel
Elevated level of plasma basic ...... th increased disease activity.
@en
P2093
P2860
P1476
Elevated level of plasma basic ...... th increased disease activity.
@en
P2093
Chiharu Kawamura
Jun-ichi Hata
Masahiro Kizaki
Naoki Shimada
Norihide Sato
Shinichiro Okamoto
Taketo Yamada
Tamihiro Kamata
Tsunayuki Kakimoto
P2860
P304
P356
10.1111/J.1349-7006.2002.TB01278.X
P577
2002-04-01T00:00:00Z